Taycha Therapeutics is a clinical-stage biotechnology company developing verekitug, a monoclonal antibody that targets the TSLP receptor to treat inflammatory diseases, starting with severe respiratory disorders including severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. The company generates no product revenue at present but is advancing verekitug through Phase 3 clinical trials with the goal of establishing it as a differentiated therapy that offers superior potency and extended dosing intervals compared to existing approved biologics. Taycha plans to commercialize verekitug across multiple therapeutic areas driven by TSLP-pathway inflammation, including dermatology and gastroenterology, by leveraging partnerships with contract manufacturers to scale production and out-licensing arrangements as a path to monetization.